Glaukos Corp Stock Price, News & Analysis

Glaukos Corporation (NYSE: GKOS), an innovative company specializing in ophthalmic medical technology, is set to release its first quarter 2023 financial results after the market closes on May 3, 2023. Following the release, management will conduct a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. Interested parties can access the webcast via Glaukos' investor relations website. The company is recognized for developing Micro-Invasive Glaucoma Surgery (MIGS) devices and aims to enhance treatment options for glaucoma, corneal disorders, and retinal diseases through continuous innovation.

Glaukos Corporation (NYSE: GKOS) announced the submission of its New Drug Application (NDA) for iDose TR to the U.S. FDA. This micro-invasive implant aims to deliver therapeutic levels of travoprost, improving patient compliance and reducing side effects of traditional glaucoma treatments. The NDA includes data from two successful Phase 3 trials confirming efficacy and safety over 12 months. CEO Thomas Burns highlighted this submission as a significant milestone, emphasizing the potential of iDose TR as a transformative therapy for glaucoma patients. The company aims to work closely with the FDA during the review process.

Glaukos Corporation (NYSE: GKOS) reported Q4 2022 net sales of $71.2 million, a 3% decline from Q4 2021. Glaucoma and Corneal Health net sales were $52.9 million and $18.3 million, respectively. Gross margin was approximately 76%, down from 77% in the previous year. SG&A expenses rose by 9% to $51.9 million, while R&D expenses surged 34% to $35.8 million. The net loss was $31.5 million, or ($0.66) per diluted share. For full year 2022, net sales totaled $282.9 million, a 4% decline year-over-year. The company provided 2023 net sales guidance of $290 million to $295 million, anticipating challenges from the macroeconomic environment.

Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, will participate in the Citi Healthcare Conference on March 1, 2023, at 1:15 p.m. ET, in New York City. The event will include a live and archived webcast accessible on the company's Investors website. Glaukos specializes in developing innovative therapies for glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) since its initial commercial launch in 2012. The company aims to enhance standard care through its diverse platforms for medical device and pharmaceutical innovations.

Glaukos Corporation (NYSE: GKOS) will announce its fourth quarter and full year 2022 financial results after market close on February 22, 2023. The company's management will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss these results. The event aims to provide insights into the company's performance, particularly in the ophthalmic medical technology sector, highlighting its ongoing commitment to innovation in glaucoma and corneal disorder treatments.

Investors can access the live webcast via Glaukos' investor relations website.